The Foundation partners with and supports organizations that develop plant- and nature-based treatments for underlying mental health issues in conjunction with substance use disorder, including those treatments outside pharmaceutical norms.Īt the 2023 conference, Etheridge will lead the session, " Addiction, family, plant medicine, and healing" where she will share how her organization is working with researchers to advance treatment approaches that address the root causes of opioid use disorder, including the mental, emotional, and spiritual aspects. I’ll also add that that's been the primary work of the MAPS public benefit corporation which is a wholly owned subsidiary of MAPS, the 501(c)(3), and the non-profit, which is also where I work, not just fully owns this for-profit drug development arm, but it also does public education, harm reduction, and policy reform, which is primarily my area of work.Etheridge, a music icon and an outspoken advocate for drug policy reform, is the founder of the Etheridge Foundation, a 501(c)3 nonprofit organization that supports groundbreaking scientific research into effective plant medicine treatments for opioid use disorder. That's the thing-we're like just a year, maybe a couple years away from. Ismail Lourido Ali: We're in the process of seeking FDA approval it would be the first indication if we are to get approval. I understand the PTSD element is one that I believe has been FDA approved is that correct? I had no idea about the treatment for autism or eating disorders-that's really fascinating. So, we're focusing primarily on PTSD as the indication for MDMA, but there are a number of investigator-initiated trials and other research about MDMA that has looked at a number of other indications, including social anxiety for adults with autism, eating disorders, couples therapy, and a few other things.Īlana Hippensteele: That is fascinating. We made it through phase 1 and 2 and made it through our first phase 3 study, and we have the hope currently of a potential line of sight on approval if all goes according to the current path by about the end of 2023. For the last 35 years, it's been working toward that goal, primarily with its flagship project of taking MDMA through the FDA approval process, so it could be prescribable as a pharmaceutical medication.Īs of today, we are in the process of recruiting for our second phase 3 study. Prior to 1985, the molecule had been used in an unregulated way in psychotherapy as an adjunct to therapeutic care, couples therapy, PTSD, and other things.Īfter it was rediscovered in the late 70s by "Sasha" Shulgin, who's a well-known chemist who passed away some years ago, MAPS was founded in 1986 with the explicit purpose and mission of creating legal cultural and medical access to the responsible use of psychedelics in society. So, MAPS was founded actually in 1986-we just celebrated our 35th anniversary, and it was founded shortly after MDMA, or 3,4-methylenedioxy-methamphetamine, was emergency scheduled by DEA in about 1985. I really appreciate the invitation-I'm really excited to talk about this, as I usually am it's a really interesting topic.
Pharmacy Times interviewed Ismail Lourido Ali, the director and counsel of policy and advocacy at the Multidisciplinary Association for Psychedelic Studies (MAPS), on psychedelic medicine policy and current advancements in the field.ĭuring the discussion, Ali addresses what MAPS is and how MAPS is engaged with the field of psychedelic medicine and its use in health care.Īlana Hippensteele: So, to start, could you tell me a bit about what MAPS is, and how MAPS is engaged with the field of psychedelic medicine and its use in health care?
0 kommentar(er)
